Single User License
INR 129080
Site License
INR 258160
Corporate User License
INR 387240

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Squamous Non-Small Cell Lung Cancer-Pipeline Review, H2 2015

Squamous Non-Small Cell Lung Cancer-Pipeline Review, H2 2015


  • Products Id :- GMDHC6982IDB
  • |
  • Pages: 157
  • |
  • August 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Squamous Non-Small Cell Lung Cancer-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Squamous Non-Small Cell Lung Cancer-Pipeline Review, H2 2015', provides an overview of the Squamous Non-Small Cell Lung Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Squamous Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Squamous Non-Small Cell Lung Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Squamous Non-Small Cell Lung Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Squamous Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Squamous Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Squamous Non-Small Cell Lung Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Squamous Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Squamous Non-Small Cell Lung Cancer Overview 9

Therapeutics Development 10

Pipeline Products for Squamous Non-Small Cell Lung Cancer-Overview 10

Pipeline Products for Squamous Non-Small Cell Lung Cancer-Comparative Analysis 11

Squamous Non-Small Cell Lung Cancer-Therapeutics under Development by Companies 12

Squamous Non-Small Cell Lung Cancer-Therapeutics under Investigation by Universities/Institutes 14

Squamous Non-Small Cell Lung Cancer-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Squamous Non-Small Cell Lung Cancer-Products under Development by Companies 18

Squamous Non-Small Cell Lung Cancer-Products under Investigation by Universities/Institutes 20

Squamous Non-Small Cell Lung Cancer-Companies Involved in Therapeutics Development 21

AbbVie Inc. 21

Advenchen Laboratories, LLC 22

Ascenta Therapeutics, Inc. 23

AstraZeneca Plc 24

AVEO Pharmaceuticals, Inc. 25

Bayer AG 26

BIND Therapeutics, Inc. 27

Boehringer Ingelheim GmbH 28

Bristol-Myers Squibb Company 29

Eli Lilly and Company 30

F. Hoffmann-La Roche Ltd. 31

Five Prime Therapeutics, Inc. 32

Genentech, Inc. 33

Incyte Corporation 34

Johnson & Johnson 35

MacroGenics, Inc. 36

Novartis AG 37

Oncogenex Pharmaceuticals, Inc. 38

PsiOxus Therapeutics Limited 39

Vertex Pharmaceuticals Incorporated 40

Squamous Non-Small Cell Lung Cancer-Therapeutics Assessment 41

Assessment by Monotherapy Products 41

Assessment by Target 42

Assessment by Mechanism of Action 45

Assessment by Route of Administration 48

Assessment by Molecule Type 50

Drug Profiles 52

abemaciclib-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

ABT-414-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

apatorsen-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

AT-406-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

atezolizumab-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

AV-203-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

AZD-2014-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

AZD-8186-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

BAY-1163877-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

BMS-906024-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

buparlisib hydrochloride-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

docetaxel-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

enadenotucirev-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

enoblituzumab-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

FP-1039-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

iMDK-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

INCB-54828-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

ipilimumab-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

JNJ-42756493-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

lucitanib-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

LY-3023414-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

necitumumab-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

nintedanib-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

prexasertib-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

Small Molecule to Inhibit TWIST1 for Non-Small Cell Lung Cancer-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

taselisib-Drug Profile 105

Product Description 105

Mechanism of Action 105

R&D Progress 105

veliparib-Drug Profile 107

Product Description 107

Mechanism of Action 107

R&D Progress 107

VX-970-Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

Squamous Non-Small Cell Lung Cancer-Recent Pipeline Updates 111

Squamous Non-Small Cell Lung Cancer-Dormant Projects 148

Squamous Non-Small Cell Lung Cancer-Discontinued Products 149

Squamous Non-Small Cell Lung Cancer-Product Development Milestones 150

Featured News & Press Releases 150

Aug 24, 2015: Five Prime Therapeutics Announces Oral Presentation of Initial Data From Ongoing Phase 1b Trial of FP-1039/GSK3052230 in Squamous Non Small Cell Lung Cancer and Mesothelioma at World Conference on Lung Cancer 150

Jul 09, 2015: Lilly Statement on FDA Advisory Committee Review of Necitumumab 150

Jun 10, 2015: Survival benefit with 'fully human' EGFR antibody necitumumab in squamous NSCLC 151

May 27, 2015: FDA Advisory Committee To Discuss On Lilly's BLA For necitumumab injection In July 2015 152

May 20, 2015: OncoGenex To Present Phase II Study Data On Apatorsen At ASCO 2015 Annual Meeting 152

Feb 24, 2015: OncoGenex and Sarah Cannon Announce Completion of Patient Enrollment in the Spruce Clinical Trial Evaluating Apatorsen in Combination with Carboplatin and Pemetrexed in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer 153

Oct 23, 2014: Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer 153

Jul 01, 2014: OncoGenex Announces Cedar Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment 154

May 14, 2014: Clovis Oncology Announces Clinical Data Of Lucitanib to Be Presented at 2014 ASCO Annual Meeting 155

Aug 13, 2013: Eli Lilly and Company's Phase III study of necitumumab meets primary endpoint 155

Appendix 156

Methodology 156

Coverage 156

Secondary Research 156

Primary Research 156

Expert Panel Validation 156

Contact Us 156

Disclaimer 157

List of Tables

Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H2 2015 10

Number of Products under Development for Squamous Non-Small Cell Lung Cancer-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 14

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Products under Development by Companies, H2 2015 18

Products under Development by Companies, H2 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H2 2015 20

Squamous Non-Small Cell Lung Cancer-Pipeline by AbbVie Inc., H2 2015 21

Squamous Non-Small Cell Lung Cancer-Pipeline by Advenchen Laboratories, LLC, H2 2015 22

Squamous Non-Small Cell Lung Cancer-Pipeline by Ascenta Therapeutics, Inc., H2 2015 23

Squamous Non-Small Cell Lung Cancer-Pipeline by AstraZeneca Plc, H2 2015 24

Squamous Non-Small Cell Lung Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 25

Squamous Non-Small Cell Lung Cancer-Pipeline by Bayer AG, H2 2015 26

Squamous Non-Small Cell Lung Cancer-Pipeline by BIND Therapeutics, Inc., H2 2015 27

Squamous Non-Small Cell Lung Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2015 28

Squamous Non-Small Cell Lung Cancer-Pipeline by Bristol-Myers Squibb Company, H2 2015 29

Squamous Non-Small Cell Lung Cancer-Pipeline by Eli Lilly and Company, H2 2015 30

Squamous Non-Small Cell Lung Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 31

Squamous Non-Small Cell Lung Cancer-Pipeline by Five Prime Therapeutics, Inc., H2 2015 32

Squamous Non-Small Cell Lung Cancer-Pipeline by Genentech, Inc., H2 2015 33

Squamous Non-Small Cell Lung Cancer-Pipeline by Incyte Corporation, H2 2015 34

Squamous Non-Small Cell Lung Cancer-Pipeline by Johnson & Johnson, H2 2015 35

Squamous Non-Small Cell Lung Cancer-Pipeline by MacroGenics, Inc., H2 2015 36

Squamous Non-Small Cell Lung Cancer-Pipeline by Novartis AG, H2 2015 37

Squamous Non-Small Cell Lung Cancer-Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2015 38

Squamous Non-Small Cell Lung Cancer-Pipeline by PsiOxus Therapeutics Limited, H2 2015 39

Squamous Non-Small Cell Lung Cancer-Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015 40

Assessment by Monotherapy Products, H2 2015 41

Number of Products by Stage and Target, H2 2015 43

Number of Products by Stage and Mechanism of Action, H2 2015 46

Number of Products by Stage and Route of Administration, H2 2015 49

Number of Products by Stage and Molecule Type, H2 2015 51

Squamous Non-Small Cell Lung Cancer Therapeutics-Recent Pipeline Updates, H2 2015 111

Squamous Non-Small Cell Lung Cancer-Dormant Projects, H2 2015 148

Squamous Non-Small Cell Lung Cancer-Discontinued Products, H2 2015 149

List of Figures

Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H2 2015 10

Number of Products under Development for Squamous Non-Small Cell Lung Cancer-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Assessment by Monotherapy Products, H2 2015 41

Number of Products by Top 10 Targets, H2 2015 42

Number of Products by Stage and Top 10 Targets, H2 2015 42

Number of Products by Top 10 Mechanism of Actions, H2 2015 45

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 45

Number of Products by Top 10 Routes of Administration, H2 2015 48

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 48

Number of Products by Top 10 Molecule Types, H2 2015 50

Number of Products by Stage and Top 10 Molecule Types, H2 2015 50

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Advenchen Laboratories, LLC

Ascenta Therapeutics, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Bayer AG

BIND Therapeutics, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Five Prime Therapeutics, Inc.

Genentech, Inc.

Incyte Corporation

Johnson & Johnson

MacroGenics, Inc.

Novartis AG

Oncogenex Pharmaceuticals, Inc.

PsiOxus Therapeutics Limited

Vertex Pharmaceuticals Incorporated

Squamous Non-Small Cell Lung Cancer Therapeutic Products under Development, Key Players in Squamous Non-Small Cell Lung Cancer Therapeutics, Squamous Non-Small Cell Lung Cancer Pipeline Overview, Squamous Non-Small Cell Lung Cancer Pipeline, Squamous Non-Small Cell Lung Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com